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Background: Adiponectin levels have been shown to be associated with colorectal cancer (CRC). Furthermore, a
newly identified adiponectin receptor, T-cadherin, has been associated with plasma adiponectin levels. Therefore,
we investigated the potential for a genetic association between T-cadherin and CRC risk.
Result: We conducted a case–control study using the Korean Cancer Prevention study-II cohort, which is composed of
325 CRC patients and 977 normal individuals. Study results revealed that rs3865188 in the 5’ flanking region of
the T-cadherin gene (CDH13) was significantly associated with CRC (p = 0.0474). The odds ratio (OR) for the TT
genotype as compared to the TA + AA genotype was 1.577 (p = 0.0144). In addition, the interaction between
CDH13 and the adiponectin gene (APN) for CRC risk was investigated using a logistic regression analysis. Among
six APN single nucleotide polymorphisms (rs182052, rs17366568, rs2241767, rs3821799, rs3774261, and rs6773957),
an interaction with the rs3865188 was found for four (rs2241767, rs3821799, rs3774261, and rs6773957). The group
with combined genotypes of TT for rs3865188 and GG for rs377426 displayed the highest risk for CRC development as
compared to those with the other genotype combinations. The OR for the TT/GG genotype as compared to the AA/AA
genotype was 4.108 (p = 0.004). Furthermore, the plasma adiponectin level showed a correlation with the gene-gene
interaction, and the group with the highest risk for CRC had the lowest adiponectin level (median, 4.8 μg/mL for
the TT/GG genotype vs.7.835 μg/mL for the AA/AA genotype, p = 0.0017).
Conclusions: The present study identified a new genetic factor for CRC risk and an interaction between CDH13
and APN in CRC risk. These genetic factors may be useful for predicting CRC risk.
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Colorectal cancer (CRC) is the third most common can-
cer in men and the second among women worldwide
[1]. While the CRC incidence rates are stabilizing or de-
creasing in historically-high risk countries, they are in-
creasing in historically low-risk countries [2]. In Korea,
the incidence rate of CRC has been continuously grow-
ing over the last 10 years, showing 7.0 and 5.3 % annual
increases in men and women, respectively [3]. CRC is
the third leading cause of cancer death in Korea, and is
the only cancer with a mortality rate that has been in-
creasing continuously for the past 10 years, while mor-
tality rates for the top two cancers fallen gradually [3, 4].* Correspondence: sjkyoon@catholic.ac.kr
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(http://creativecommons.org/publicdomain/zeThe increase in the CRC incidence rate in Korea is
thought to be associated with changes towards a Western
diet and lifestyle which results in obesity. This is signifi-
cant, as obesity has been reported to be associated with a
high risk for CRC [5–7], and abdominal obesity was
shown to be an independent risk factor for colon cancer
as well [8]. In obese individuals, plasma adiponectin con-
centrations are low, and such levels have been shown to
be associated with risk for CRC. This implies that de-
creased expression of adiponectin may be associated with
increased risk for CRC development [9, 10].
Adiponectin, an abundant plasma protein exclusively
expressed and secreted from adipocytes, modulates meta-
bolic processes including the regulation of glucose levels
and fatty acid oxidation. Through these mechanisms, adi-
ponectin suppresses metabolic derangements that may re-
sult in type 2 diabetes (T2DM), obesity, atherosclerosis,
non-alcoholic fatty liver disease, and metabolic syndrome.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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acterized by obesity and T2DM [11, 10]. The results from
numerous studies have supported a relationship between
plasma adiponectin levels and risk for CRC [12, 10, 13],
and variants of the adiponectin gene (APN) have been
shown to be associated with CRC risk [14, 15].
As an endogenous insulin sensitizer, adiponectin ex-
erts its action through two G-protein coupled receptors,
adiponectin receptor 1 (AdipoR1) and adiponectin
receptor 2 (AdipoR2), which are expressed in colonic tis-
sue [16, 17]. Adiponectin has been shown to suppress
cell proliferation via activation of AdipoR1 and -R2
mediated 5' adenosine monophosphate-activated protein
kinase (AMPK) in colon cancer cells [18]. Additionally,
several polymorphisms of APN and AdipoR1 have been
shown to be associated with risk for CRC in various
populations [19, 14, 20].
Recently, the third member of the adiponectin recep-
tor family, CDH13, was found, and classified as a mem-
ber of the cell surface glycoprotein family, functioning as
a signaling transducer as well as a cell-cell adhesion
molecule [21]. Loss of expression and aberrant methyla-
tion of the CDH13 gene has been demonstrated in colo-
rectal cancer [22, 23]. However, an association between
the CDH13 gene and CRC risk has yet to be described.
In the present study, we identified the nature of the
association between CDH13 and CRC, and found that
the interaction between APN and CDH13 was related to
both the CRC risk and the plasma adiponectin level.
Methods
Ethics statement
Written informed consent was obtained from all study
participants. The study was performed in accordance
with the guidelines established by the Catholic Medical
Center Office of Human Research Protection Program,
and approved by the Institutional Review Boards of the
Catholic University of Korea and Yonsei University.
Study population
The study population was composed of 325 confirmed
CRC patients from the Korean Cancer Prevention study-
II (KCP-II), which included 200,595 individuals recruited
from 16 health promotion centers nationwide. Patients
were categorized as having CRC based on the Inter-
national Classification of Diseases for Oncology (ICD-O)
at the National Cancer Center of Korea [24]. As con-
trols, randomly selected 1004 individuals with lack of
CRC based on anamnesis and family history in the KCP-
II were genotyped using Human SNP array 5.0 (Affyme-
trix, Santa Clara, CA, USA) and individuals with low
genotyping call rates (<95 %) removed. And so were the
ones with missing anthropometric measurement (SBP,
DBP, waist circumference and BMI) or gender mismatchbetween genpotype and self-reported information. Thus,
977 normal individuals in the KCP-II were included for
the present study [25] (Additional file 1: Figure S1). Ge-
notypes of the control participants were previously
determined using the same platform as was used in the
present study [25]. Recorded and analyzed clinical char-
acteristics of the participants included age, sex, systolic
blood pressure (SBP), diastolic blood pressure (DBP),
waist circumference (WC), body mass index (BMI), and
plasma adiponectin level. Each participant was measured
for weight and height while wearing light clothing, and
BMI was calculated as mass (kg) divided by height in
meters squared (m2). SBP and DBP were measured after
a 15 min rest. Serum was separated from peripheral
venous blood and the adiponectin level was measured
using an ELISA kit following the manufacturer’s proto-
col (Mesdia, Korea) [26].
Genotyping and single nucleotide polymorphism (SNP)
selection
Genomic DNA isolated from the peripheral blood of par-
ticipants was utilized for genotyping using the Human
SNP Array 5.0 (Affymetrix, Santa Clara, CA, USA) at
DNAlink Inc. (Seoul, Korea). For data accuracy, an internal
quality control (QC) measurement was used: QC call rate
(dynamic model algorithm) always exceeded > =86 %, and
contrast QC <0.4. The heterozygosity of X chromosome
markers identified the sex of each sample. Genotype calling
was accomplished using the Birdseed (v2) algorithm. The
genotype call rate for six APN SNPs (rs182052, rs17366568,
rs2241767, rs3821799, rs3774261, and rs6773957) and one
CDH13 SNP (rs3865188) were all above 95 %.
The single CDH13 SNP (rs3865188) was selected due
to its previously identified association with plasma adi-
ponectin levels [27]. In addition, all SNPs in APN on the
chip were analyzed. The linkage disequilibrium (LD)
between the APN SNPs was determined using Haplo-
view 4.2 (Additional file 2: Figure S2).
Statistical analysis
The T-test or X2 test was used to examine the differ-
ences in the distribution of demographic and clinical
characteristics, as well as genotype frequencies between
cases and controls. Hardy-Weinberg equilibrium (HWE)
was also analyzed using the X2 test. A logistic regression
analysis was used to evaluate the CRC risk associated
with the genotype of each SNP, as well as the interac-
tions between genotypes in comparison to control par-
ticipants. The odds ratio (OR) and 95 % confidence
intervals (CI) of CRC associated with CDH13 and
APNSNP genotypes was computed and adjusted for age,
sex, and BMI. The T-test and analysis of variance test
were used for normally distributed variables. Nonpara-
metric tests included the Wilcoxon signed rank test and
Table 2 Genotype distribution of CDH13 and APN SNPs with
respect to CRC in KCP-II
Gene SNP Group (n) Genotype p-value
Frequency
CDH13 rs3865188 AA AT TT
Case (325) 0.4646 0.3815 0.1538 0.0474 *
Control (977) 0.4862 0.4104 0.1034
APN rs182052 AA AG GG
Case (325) 0.2646 0.5077 0.2277 0.4161
Control (974) 0.2402 0.4979 0.2618
rs1736656 AA AG GG
Case(325) 0.0000 0.5540 0.9446 0.4235
Control (977) 0.0100 0.3990 0.9591
rs2241767 AA AG GG
Case (325) 0.4954 0.4246 0.0800 0.7045
Control (977) 0.5067 0.4023 0.0811
rs3821799 CC CT TT
Case (325) 0.1692 0.4677 0.3631 0.3357
Control (968) 0.1395 0.4638 0.3967
rs3774261 AA AG GG
Case (324) 0.3179 0.5062 0.1759 0.1516
Control (972) 0.3755 0.4743 0.1502
rs6773957 AA AG GG
Case (325) 0.3169 0.5046 0.1785 0.1417
Control (977) 0.3756 0.4719 0.1525
*: P < 0.05
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tically significant at p < 0.05. Statistical analyses were
conducted using SAS software (ver. 9.2).
Results
General characteristics of study participants
The distribution of the demographic and clinical charac-
teristics of the 325 CRC patients and 977 controls are
shown in Table 1. The CRC patients were older with a
greater proportion of males than the control group.
They also had higher SBP, DBP, and BMI, and thicker
WCthan controls. However, no difference in adiponectin
levels was found between cases and controls.
Associations between SNPs and CRC
The genotype distributions of all SNPs were in HWE in
the control group (Additional file 3: Table S1, p > 0.2). A
significant association was found only between the
CDH13 SNP rs3865188 and CRC; none of the six APN
SNPs showed evidence of any association with CRC. The
frequencies of rs3865188 AA, AT, and TT genotypes
were 0.4646, 0.3815, and 0.1538, respectively, in patients
as compared to 0.4862, 0.4104, and 0.1034, respectively,
in controls (p = 0.0474; Table 2). The logistic regression
analysis revealed that the individuals with an rs3865188
TT genotype had an increased risk of developing CRC as
compared to the individuals with the other genotypes
(AT or AA) in the recessive mode only (OR = 1.577,
95 % CI 1.095–2.272, p = 0.0144; Table 3). The risk esti-
mate remained significant after adjustment for age and
BMI, and showed a tendency toward risk even after an
additional adjustment for sex (Table 3).
Gene-gene interaction for CRC risk
Whether the presence of both variants could influence
the risk for CRC was determined between rs3865188
and each of the six APN SNPs. Among the six SNPs,
fourshowed an interaction with rs3865188 such that
the combined genotypes were significantly associated
with CRC risk. Those four SNPs, rs2241767, rs3821799,
rs3774261, and rs6773957, formed an LD blockTable 1 General characteristics of the study participants in Korean C
Total
Normal participants (n = 977)
Male(%) 56.5
Age (year) 41.26 ± 8.44
SBP(mmHg) 120.66 ± 13.79
DBP(mmHg) 73.76 ± 10.39
WC(cm) 81.30 ± 9.52
BMI(Kg/m2) 23.66 ± 3.12
Adiponectin(μg/ml) 8.33 ± 5.78
SBP; systolic blood pressure, DBP; diastolic blood pressure, WC; waist circumference(Additional file 1: Figure S1). Among individuals with an
rs3865188TT genotype, a significant change in CRC risk
was not observed for individuals who carried wild type
alleles for all four SNPs when compared to controls. In
contrast, among those with an rs3865188 TT genotype,
those whose genotypes were homozygous for the variant
allele for each SNP had a much higher risk for CRC devel-
opment as compared to the other genotype combinations
(Fig. 1).ancer Prevention Study II (KCP-II)
p-value
Colorectal caner patients (n = 325)
72.9
52.82 ± 10.33 <.0001
123.07 ± 16.43 0.011
76.23 ± 11.51 <.0001
84.42 ± 8.79 <.0001
24.17 ± 2.91 0.0095
7.68 ± 4.85 0.3300
, BMI; Body mass index
Table 3 rs3865188 of CDH13 association analyses with risk of CRC in this study
Unadjusted Adjusted for age and BMI Adjusted for age, sex and BMI
T-dominance Point estimate 1.090 1.150 1.135
95 % Confidence intervals 0.848–1.402 0.860–1.539 0.847–1.521
p-value 0.5003 0.3451 0.3972
T-recessive Point estimate 1.577 1.575 1.526
95 % Confidence intervals 1.095–2.272 1.029–2.410 0.991–2.352
p-value 0.0144* 0.0366* 0.0552
T-Dominance;TT + TAvs. AA T-recessive; TT vs. TA + AA, *: P < 0.05
Park et al. Journal of Biomedical Science  (2015) 22:73 Page 4 of 8Individuals with the combined genotype of TT for
rs3865188 and GG for rs3774261 had the most signifi-
cantly increased CRC risk as compared to those with the
other genotype combinations (Fig. 1a, OR = 4.108, 95 %
CI 1.568–10.763, p = 0.004). Risks for CRC developmentFig. 1 Adjusted odds ratios for colorectal cancer risk by interaction betwee
interaction, *; p = 0.004, b) rs3865188-rs2241767 interaction, †; p = 0.0402, c)
interaction,₤; p = 0.0064. Adjusted for age, sex and BMIdue to interaction with rs3865188 were also increased
with rs2241767 (Fig. 1b, OR = 2.495, 95 % CI 1.042–5.943,
p = 0.0402), rs3821799 (Fig. 1c, OR = 3.491, 95 % CI
1.259–9.679, p = 0.0163), and rs6773957 (Fig. 1d, OR =
3.954, 95 % CI 1.471–10.629, p = 0.0064). However,n rs3865188 and each of the four APN SNPs. a rs3865188-rs3774261
rs3865188-rs3821799 interaction,‡; p = 0.0163, d) rs3865188-rs6773957
Fig. 2 Difference in the plasma adiponectin level based on gene-gene
interaction in KCP study-II. The median plasma adiponectin levels
were7.835 and 4.800 μg/ml for individuals with the genotype
combination of rs3865188:AA/rs3774261:AA and rs3865188:TT/
rs3774261:GG, respectively
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CRC independently nor interacted with rs3865188 for
CRC risk.
Correlation of the combined genotype with the
adiponectin level
Because rs3865188 was shown to be associated with the
plasma level of adiponectin, and low levels of adiponec-
tin were reported to be related to CRC risk [27], we
investigated whether an association with CRC by gene-
gene interaction was correlated with the plasma adipo-
nectin level. The plasma adiponectin level was analyzed
using nonparametric tests.
The plasma adiponectin level was significantly lower
in the groups with the risk genotype combination than
in those with the other genotype combinations for all
SNP pairs. Individuals with a TT genotype for rs3865188
and a GG genotype for rs3774261 had the lowest
plasma adiponectin levels as compared to those with
the AA genotype for rs3865188 and the AA genotype
for rs3774261 (Fig. 2, rs3865188:AA/rs3774261:AA
median = 7.83 μg/ml, rs3865188:TT/rs3774261:GG
median = 4.80 μg/ml, p = 0.0017). A similar pattern
was seen in the pairs of other genotype combinations
(Additional file 3: Table S2).
Discussion
This is the first study to examine gene-gene interactions
between genetic variants of adiponectin and its new re-
ceptor, CDH13, with reference to CRC. Additionally, the
present study also demonstrated the significant gene-
gene interactions betweenCDH13 rs3865188 and APN
SNPs in a LD block in relation to the risk for CRC, withthe combination of the rs3865188 TT and rs3774261
GG genotypes having the highest risk. Of interest, this
risk increase was consistent with low adiponectin levels.
Adiponectin and its pathway have been implicated in
the carcinogenesis of multiple cancers including CRC
[28]. Adiponectin has been associated with metabolic
syndrome, T2DM, and obesity [29–31], which are known
risk factors for CRC [7, 32]. The results from several
studies have indicated that adiponectin mRNA and
plasma levels were decreased in patients with obesity
and T2DM [33, 34], implicating adiponectin as a key
player in the development of obesity and insulin resist-
ance. Because this characteristic of adiponectinis attrib-
utable to carcinogenesis, the roles of adiponectin and its
receptors have been studied in carcinogenesis [35–37].
APN SNPs have been controversial in CRC carcinogen-
esis association studies, as no single SNP has been consist-
ently associated across the different studies [38–40]. While
the APN gene was found not to be associated with CRC in
the UK and US (New York) [38, 39], contrary results were
found in a Chinese population [38]. The most recent large
meta-analysis on the subject revealed that rs2241766 alone
showed an association with CRC in a specific genetic
mode. In our study, none of the six APN SNPs were associ-
ated with either CRC risk or adiponectin levels. The
rs3774261 and rs6773957APN SNPs were shown to be
associated with adiponectin levels in an American popula-
tion [41]. Furthermore, rs1063538, which is in LD with
these two SNPs was shown to have an association with
CRC risk in a Chinese population [40]. The rs3774261 and
rs6773957 SNPs had lower p-values than the other four
SNPs, however, no associations with CRC risk or adiponec-
tin levels were found in our study. Instead, we documented
that these SNPs showed gene-gene interactions with
rs3865188 for CRC risk and adiponectin levels. Thus, a
replication study with larger sample is required to clarify
the nature of the relationship between APN variants and
CRC risk in Koreans. Interestingly, four SNPs (rs2241767,
rs3821799, rs3774261, and rs6773957) of the six APN SNPs
formed an identical LD block in the Eastern Asians includ-
ing Korean population, CHB; Han Chinese in Bejing,
China, JPT; Japanese in Tokyo, Japan, whereas those did
not in Caucasians such as CEU; Utah Residents with
Northern and Western European Ancestry (HapMap pro-
ject). Furthermore, it has been shown that rs3865188 is
also highly associated with plasma APN levels in Filipinos,
and Japanese as well [42, 43]. Thus, there is a possibility
that gene-gene interaction between a CDH13 SNP and adi-
ponectin SNPs may affect East Asians and a further study
is required to clarify this relationship.
CRC risk is mediated through APN receptors, as well
as through APN. The results of a previous study using
classification and regression tree analysis indicated that
an environmental factor was associated with risk for
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APN and rs1539355 of AdipoR1 [40]. Results from an
additional study demonstrated that adiponectin medi-
ated AMPK activity via AdipoR1 and AdipoR2 in a colon
cancer cell line [18]. AMPK plays critical roles in the
regulation of glucose metabolism, insulin sensitivity, and
lipid metabolism [44], all of which are correlated with
tumorigenesis in humans [45]. Additionally, polymor-
phisms related to insulin resistance and obesity have
been reported to be associated with CRC risk [46]. Thus,
we anticipated that a receptor gene of APN may play an
important role in the carcinogenesis of CRC.
Although we observed a marginal association of a
CDH13 polymorphism and no association of APN poly-
morphisms with CRC, the interaction of these SNPs
showed significant associations with the risk of CRC,
suggesting that APN function via CDH13 should be con-
sidered in regard to CRC risk.
CDH13 expression was found in adult brain, lung,
heart and blood vessels [47] and shown to be modulated
by various factors such as FGF-2 [48], oxidative stress
[49], progesterone, estradiol and serum factors [50], and
zeb1 [51]. However, CDH13 expression in different
ethnic groups has not been currently known.
The biological function of CDH13 remains largely
unknown. However, it is a known APN receptor, and
binding of the high molecular weight form of APN to
CDH13 transduces signals and activates AMPK activity
[44]. Furthermore, CDH13 is known to function as a
tumor suppressor gene, and suppression of CDH13
expression by aberrant methylation in the CpG island of
its promoter has been reported in CRC [23, 52] and
other types of cancers [53–55]. Thus, we suggest that
pathological regulation affected by the interaction be-
tween CDH13 and APN may be mediated through
AMPK in CRC.
Epidemiologic studies have identified sexual dimorph-
ism in CRC risk, with a higher incidence and earlier onset
in men [56] and female hormones have been suggested to
play a protective role in CRC development [57]. Interest-
ingly, we observed that rs3865188of CDH13was signifi-
cantly associated with CRC risk in male (p = 0.049) but
not in female (p = 0.880). Recently, circulating T-cadherin
and high molecular weight adiponecin levels were shown
to be negatively associated in angiographically stable
coronary artery young male patients but not in female
patients [58]. Therefore, male-specific CDH13 association
in CRC risk could have a sex-specific contributing fac-
tor(s) involved. Clearly, further study with larger number
of participantsis required to identify an underlying factor
for this observation.
The present study was not without limitations. First,
our sample size was limited. We selected 325 CRC
patients and 977 normal individuals from the KCP-II.Further study will be needed in order to analyze more
Koreans and members of other ethnic groups. Second,
our study only identified interactions between genetic fac-
tors with respect to CRC risk, and therefore we did not in-
vestigate relationships between genetic factors and clinical
information (cancer staging, drug treatment, other dis-
order). Additional studies will be required in order to
more fully elucidate the nature of the correlations between
clinical information, CRC, and gene-gene interactions.
Conclusion
Nevertheless, we found a new gene-gene interaction with
respect to CRC risk is uncovered, and identified a correl-
ation between adiponectin level and the combined geno-
type. Our study suggests that gene-gene interaction
between a CDH13 SNP and adiponectin SNPs is a CRC risk
genetic marker for predisposition in Korean population.
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